About TxCell
April 24, 2013
Dr. Miguel Forte will present at the 19th ISCT Annual Meeting
Auckland, NZ
"One year multiple injections of antigen specific T regulatory lymphocytes in refractory Crohn's disease patients, extension of CATS1 study"
P. Desreumaux et all.
Treg: Regulatory T Cells and T Helper Cells
|
|
|
Based in Sophia-Antipolis, a large business park near Nice in France, TxCell is a biotechnology company founded in 2001 as a spin-off from the Institut National de la Santé et de la Recherche Médicale (INSERM). The company’s technology is based on the pioneering work of the founding scientist, who co-discovered in 1997 the type 1 regulatory T lymphocytes. TxCell has been funded by venture capital since 2004 and a total of 36.3M€ has been invested through three rounds of financing by five major investors Auriga Partners, AXA Private Equity, CDC Entreprises, Innovation Capital and Seventure Partners. |
|
